Reporting Manager
Sphera Funds Management Ltd.
Symbol
OTLK
Shares outstanding
34,331,455 shares
Disclosed Ownership
2,571,426 shares
Ownership
7.5%
Form type
SCHEDULE 13G/A
Filing time
10 Apr 2025, 17:28:06 UTC
Date of event
10 Apr 2025
Previous filing
03 Mar 2025
Next filing
05 Feb 2026

Key filing fact

SPHERA FUNDS MANAGEMENT LTD. disclosed 7.5% ownership in Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK) on 10 Apr 2025.

Key facts

  • SPHERA FUNDS MANAGEMENT LTD. filed SCHEDULE 13G/A for Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share (OTLK).
  • Disclosed ownership: 7.5%.
  • Date of event: 10 Apr 2025.

Change

  • Previous schedule filing date: 03 Mar 2025.
  • Current filing was accepted on 10 Apr 2025, 17:28.

Research use

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting persons

Reporting managers (3)

Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Sphera Funds Management Ltd. 7.5% 2,571,426 0 2,571,426 /s/ Adi Hanetz Adi Hanetz / General Counsel
Sphera Global Healthcare GP Ltd. 7.5% 2,571,426 0 2,571,426 /s/ Adi Hanetz Adi Hanetz / General Counsel
Sphera Global Healthcare Management LP. 7.5% 2,571,426 0 2,571,426 /s/ Adi Hanetz Sphera Global Healthcare Management LP.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .